Reprogramming is the
next leap forward in cancer immunotherapy

Direct Cell Reprogramming
Cancer Immunotherapy

Asgard Therapeutics

Asgard Therapeutics is a Swedish private biotech company exploring direct cell reprogramming technologies to develop ground-breaking cancer immunotherapies. Incorporated as a spin-off from Lund University, Asgard is pioneering gene therapy approaches with the proprietary lead program AT-108, designed to set in motion immune responses mediated by the biological properties of professional antigen presenting cells. Designed as an off-the-shelf gene therapy, Asgard´s approach overcomes many of the logistic and manufacturing hurdles of conventional cell-based therapies.

Read more
Co-founder and CEO Cristiana Pires explains the lead program AT-108 concept
Play video
Asgard’s team: Michele Tavecchio, Fritiof Åkerström, André Rosa
Filipe Pereira, Cristiana Pires and Fábio Rosa

Our Team

Asgard Therapeutics brings together a growing team of experts in the cell reprogramming, gene therapy and immuno-oncology fields to guide our mission and develop pioneering off-the-shelf gene therapies based on the lead program AT-108.

Meet the members of our Executive Team and Board of Directors.

Read more